Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Feb;39(2):235-248.
doi: 10.1002/mds.29700. Epub 2024 Jan 17.

Management of Impulse Control and Related Disorders in Parkinson's Disease: An Expert Consensus

Ines Debove  1 , Steffen Paschen  2 , Deborah Amstutz  1 , Francisco Cardoso  3 , Jean-Christophe Corvol  4 , Victor S C Fung  5 , Anthony E Lang  6   7 , Pablo Martinez Martin  8 , María C Rodríguez-Oroz  9 , Daniel Weintraub  10   11 , Paul Krack  1 , Günther Deuschl  2 ; and the Members of the ICBD in PD Management Consensus Group
Collaborators, Affiliations
Free article
Review

Management of Impulse Control and Related Disorders in Parkinson's Disease: An Expert Consensus

Ines Debove et al. Mov Disord. 2024 Feb.
Free article

Erratum in

Abstract

Background: Impulse-control and related behavioral disorders (ICBDs) significantly impact the lives of Parkinson's disease (PD) patients and caregivers, with lasting consequences if undiagnosed and untreated. While ICBD pathophysiology and risk factors are well-studied, a standardized severity definition and treatment evidence remain elusive.

Objective: This work aimed to establish international expert consensus on ICBD treatment strategies. To comprehensively address diverse treatment availabilities, experts from various continents were included.

Methods: From 2021 to 2023, global movement disorders specialists engaged in a Delphi process. A core expert group initiated surveys, involving a larger panel in three iterations, leading to refined severity definitions and treatment pathways.

Results: Experts achieved consensus on defining ICBD severity, emphasizing regular PD patient screenings for early detection. General treatment recommendations focused on continuous monitoring, collaboration with significant others, and seeking specialist advice for legal or financial challenges. For mild to severe ICBDs, gradual reduction in dopamine agonists was endorsed, followed by reductions in other PD medications. Second-line treatment strategies included diverse approaches like reversing the last medication change, cognitive behavior therapy, subthalamic nucleus deep brain stimulation, and specific medications like quetiapine, clozapine, and antidepressants. The panel reached consensus on distinct treatment pathways for punding and dopamine dysregulation syndrome, formulating therapy recommendations. Comprehensive discussions addressed management strategies for the exacerbation of either motor or non-motor symptoms following the proposed treatments.

Conclusion: The consensus offers in-depth insights into ICBD management, presenting clear severity criteria and expert consensus treatment recommendations. The study highlights the critical need for further research to enhance ICBD management. © 2024 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Keywords: Parkinson's disease; deep brain stimulation; impulse-control and related behavioral disorders.

PubMed Disclaimer

References

    1. Baig F, Kelly MJ, Lawton MA, et al. Impulse control disorders in Parkinson disease and RBD: a longitudinal study of severity. Neurology 2019;93(7):e675-e687. https://doi.org/10.1212/WNL.0000000000007942
    1. Lawrence AD, Evans AH, Lees AJ. Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry? Lancet Neurol 2003;2(10):595-604. https://doi.org/10.1016/S1474-4422(03)00529-5
    1. Cilia R, Siri C, Canesi M, et al. Dopamine dysregulation syndrome in Parkinson's disease: from clinical and neuropsychological characterisation to management and long-term outcome. J Neurol Neurosurg Psychiatry 2014;85(3):311-318. https://doi.org/10.1136/jnnp-2012-303988
    1. Warren N, O'Gorman C, Lehn A, Siskind D. Dopamine dysregulation syndrome in Parkinson's disease: a systematic review of published cases. J Neurol Neurosurg Psychiatry 2017;88(12):1060-1064. https://doi.org/10.1136/jnnp-2017-315985
    1. Eusebio A, Witjas T, Cohen J, et al. Subthalamic nucleus stimulation and compulsive use of dopaminergic medication in Parkinson's disease. J Neurol Neurosurg Psychiatry 2013;84(8):868-874. https://doi.org/10.1136/jnnp-2012-302387

MeSH terms